Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-348 SAD in Healthy Volunteers
NCT02108106Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pyruvate kinase deficiency (PKD) comparing AG-348 with Placebo (2 arms). Primary endpoint: Safety and tolerability at 11 days. Started Mar 2014; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT02108106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108106.